Table 2.
Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR uncorrected
| Year | Drug/site | N | PD3 | Excluded/lost | LCF | LPF | ACPR | Kaplan–Meier |
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | |||
| 2011 | ASAQ | |||||||
| Ujiji | 73 | 0 | 8 (11.0) | 13.8 (6.5–24.7) | 10.8 (4.4–20.9) | 75.4 (63.1–85.2) | 76.1 (64.0–84.6) | |
| Kibaha | 29 | 0 | 4 (13.8) | 0 (0.0–13.7) | 0 (0.0–13.7) | 100 (86.3–100) | 100 | |
| AL | ||||||||
| Muheza | 32 | 2 (6.3) | 2 (6.3) | 0 (0.0–11.6) | 3.3 (0.1–17.2) | 96.7 (82.8–99.9) | 96.9 (79.8–99.6) | |
| 2012 | AL | |||||||
| Chamwino | 26 | 0 | 3 (11.5) | 0 (0.0–14.8) | 4.3 (0.1–21.9) | 95.7 (78.1–99.9) | 95.7 (72.9–99.4) | |
| Kyela | 44 | 0 | 8 (18.2) | 5.6 (0.7–18.7) | 16.7 (6.4–32.8) | 77.8 (60.8–89.9) | 78.9 (62.3–88.9) | |
| Nagaga | 62 | 0 | 23 (37.1) | 0 (0.0–9.0) | 0 (0.0–9.0) | 100 (91.0–100) | 100 | |
| 2015 | AL | |||||||
| Kyela | 80 | 0 | 16 (20.0) | 4.7 (1.0–13.1) | 1.6 (0.0–8.4) | 93.8 (84.8–98.3) | 94.1 (85.0–97.8) | |
| DHA-PQ | ||||||||
| Rufiji | 82 | 0 | 10 (12.2) | 1.4 (0.0–7.5) | 0 (0.0–5.0) | 98.6 (92.5–100) | 98.6 (90.8–99.8) | |
PD3 positive on day 3, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate + amodiaquine, AL artemether + lumefantrine, DHAPQ dihydroartemisinin + piperaquine